A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device

Trial Details

NCT ID
NCT07227831
Phase
NA
Sponsor
Barbara Ann Karmanos Cancer Institute
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • TheraBionic P1
Locations (sample)
  • Bay City, Michigan, United States|43.59447,-83.88886
  • Clarkston, Michigan, United States|42.73586,-83.41883
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Flint, Michigan, United States|43.01253,-83.68746
  • Lapeer, Michigan, United States|43.05142,-83.31883

Key Eligibility Criteria

  • Participant must have locally advanced/unresectable or metastatic Hormone Receptor (HR) positive, Human Epidermal growth factor receptor 2 (HER2) n…
  • Participant must have received and progressed on or are intolerant to all therapies known to confer overall survival benefit, including at least on…
  • Participant must be a woman ≥ 22 years old and must be able to understand and sign an informed consent form.
  • Participant must have a life expectancy of at least 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →